key: cord-1001069-e4fdih9t authors: Kasperkiewicz, M.; Yale, M.; Strong, R.; Zillikens, D.; Woodley, D.T.; Recke, A. title: COVID‐19 pandemic and autoimmune bullous diseases: a cross‐sectional study of the International Pemphigus and Pemphigoid Foundation date: 2021-03-29 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17228 sha: af7181cb627cc47f6e85593ea6d1bf96833dc384 doc_id: 1001069 cord_uid: e4fdih9t Autoimmune bullous diseases (AIBDs) are rare and potentially life-threatening chronic inflammatory disorders that are difficult to manage during the COVID-19 outbreak.1,2 Our objective was to investigate the associations of outdoor activity restriction, income loss, and treatment non-adherence with self-reported outcomes as well as to determine the satisfaction level with teledermatology platforms in patients with AIBDs during the COVID-19 pandemic. Editor Autoimmune bullous diseases (AIBDs) are rare and potentially life-threatening chronic inflammatory disorders that are difficult to manage during the COVID-19 outbreak. 1, 2 Our objective was to investigate the associations of outdoor activity restriction, income loss and treatment non-adherence with self-reported outcomes and to determine the satisfaction level with teledermatology platforms in patients with AIBDs during the COVID-19 pandemic. In this cross-sectional study, English-speaking AIBD patients aged >18 years, who were recruited from the database of the International Pemphigus and Pemphigoid Foundation, were asked to complete a COVID-19 pandemic-related Web-based survey between 30 July 2020 and 1 October 2020. The online poll and its rating system were adapted with minor modifications from Kuang et al., 3 Wang et al. 4 and Ruggiero et al. 5 Electronic informed consent was obtained from all patients, and the questionnaire was completed anonymously. The study was granted exemption by the Institutional Review Board of the University of Southern California. The primary outcome was deterioration of the disease, determined by the Global Rating of Change. The secondary outcomes included perceived stress and symptoms of anxiety and depression, which were assessed by the visual analogue scale, 2-item Generalized Anxiety Disorder and 2-item Patient Health Questionnaire, respectively. The cut-off points were ≥7, ≥3 and ≥3, respectively, according to previous studies. 3, 4, [6] [7] [8] The tertiary outcome was the satisfaction level of patients using telemedicine platforms (i.e. live interactive video-call visits). Logistic regression was used to estimate associations with adjustments for potential confounders. The effect size is presented as odds ratio, likelihood ratio and 95% confidence interval. P values < 0.05 were considered statistically significant. Valid questionnaires including location data were collected from a total of 383 patients [276 females and 107 males; aged 19-95 (mean 59.9) years; 207 pemphigus vulgaris, 75 mucous membrane pemphigoid, 59 bullous pemphigoid, 31 pemphigus foliaceus and 11 other AIBDs]. Responses to the online questionnaire came from North America (n = 320), Europe (n = 26), Asia (n = 15), South America (n = 11), Africa (n = 4), Australia (n = 4) and New Zealand (n = 3). Eleven (2.8%) patients reported confirmed infection with SARS-CoV-2. 35.2% patients reported a moderate to great exacerbation of their AIBD. The proportions of perceived stress, anxiety and depression were 32.4%, 35% and 31.9%, respectively. Outdoor activity restriction was associated with stress, anxiety and depression. Income loss was associated with stress and depression. Treatment non-adherence was associated with disease aggravation. After adjustment for confounders, relationships remained between outdoor activity restriction and anxiety as well as between income loss and depression. Confounder adjustment further revealed an association between income loss and disease deterioration (Table 1) . Thirty-five (9.1%) patients consistently reported to have consulted a dermatologist through telemedicine platforms, and there was a high satisfaction level (score 7-10) in the majority of patients (72.4-90.3%) who used this virtual healthcare service through videoconferencing ( Table 2) . †Adjusted for location of study participants, age, gender, education, annual income, marital status, comorbidities, disease type, disease duration, affected body surface area, mucosal involvement, income loss, treatment non-adherence and COVID-19 status. ‡Twelve out of these patients reported increased income. Our results emphasize the negative impact of the COVID-19 outbreak on health outcomes in patients with AIBDs and indicate a high satisfaction with telemedicine platforms at this difficult time, although the prevalence rates of stress, anxiety and depression were comparable to the general population during the COVID-19 pandemic (i.e. 29.6%, 31.9% and 33.7%, respectively). 9 Appropriate healthcare delivery solutions, including a public mental health response, are required to improve the health of vulnerable individuals in the COVID-19 era. (F) What is the likelihood that you would use this dermatology telemedicine service again? 1 Six patients did not provide a score. 2 Three patients did not provide a score. 3 Four patients did not provide a score. [4] [5] [6] Numbers (in italic) represent the sum of scores 0-3, 4-6 and 7-10, respectively. © 2021 European Academy of Dermatology and Venereology Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic COVID-19 outbreak and autoimmune bullous diseases: a systematic review of published cases Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: a web-based survey Nonadherence to treatment and patientreported outcomes of psoriasis during the COVID-19 epidemic: a webbased survey Teledermatology for acne during COVID-19: high patients' satisfaction in spite of the emergency Validity of occupational stress assessment using a visual analogue scale Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis The patient health questionnaire-2: validity of a two-item depression screener Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis Follow-up of dermatological manifestations in non-critical hospitalized patients with COVID-19 pneumonia and their prognostic correlation with disease severity Dear Editor, COVID-19 is currently one of the main causes of death worldwide. This virus affects mainly the lower respiratory system, but significant damage to other organs has been observed. Cutaneous manifestations related to the aforementioned viral infection have been reported with an incidence that ranges between 0.20% and 20%. The period between the appearance of cutaneous lesions and COVID-19 infection remains uncertain. 1, 2 With the information that exists, one can speculate that cutaneous manifestations of COVID-19 can be classified into two groups Figure 1 In this graphic, patients with cutaneous manifestations (blue dots) and without cutaneous manifestations (green dots) are plotted according to their prognosis using clinical and biochemical variables. The red box represents patients with a P/F ratio >200 and CRP <11 mg/dL. The grey box represents patients with a P/F ratio >200 and CRP >11 mg/dL. The black box represents patients with a P/F ratio <200 and CRP >11 mg/dL.